Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00273936 | Trial of AVN-944 in Patients With Advanced Hematologic Malignancies | PHASE1 | COMPLETED | 72 | — | — | Jan 1, 2006 | - | Aug 4, 2011 | 5 | United States |
| Name | Type | Description |
|---|---|---|
| AVN-944 capsules for oral administration | DRUG | - |
Inclusion Criteria: 1. Histologically or cytologically confirmed chronic myelogenous leukemia, acute myeloid leukemia, acute lymphocytic leukemia, multiple myeloma, Waldenstrom's macroglobulinemia, non-Hodgkin's lymphoma or Hodgkin's disease. 2. Patients must be refractory to, intolerant of, or dec...